Form 4: Pliant Therapeutics CFO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Pliant Therapeutics' Chief Financial Officer, Keith Lamont Cummings, sold 20,148 shares of common stock to cover tax liabilities related to vesting restricted stock units.
Summary
- Keith Lamont Cummings, the Chief Financial Officer of Pliant Therapeutics, sold 20,148 shares of common stock on January 17, 2025.
- The sale was executed at a weighted average price of $11.2011 per share, with individual prices ranging from $11.03 to $11.695.
- This transaction was part of a plan to cover withholding tax liabilities associated with the vesting of previously granted restricted stock units.
- The sale was nondiscretionary and conducted by a broker on behalf of a group of employees, including Mr. Cummings.
- Following the transaction, Mr. Cummings beneficially owns 262,608 shares of Pliant Therapeutics common stock, which includes 641 shares acquired through an Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction for an executive to cover tax obligations. It is neither positive nor negative for the company's outlook.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when restricted stock units vest.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations are a common practice across the industry.
- Many companies use Rule 10b5-1 plans to allow executives to sell shares in a pre-planned manner, avoiding accusations of insider trading.
- The sale price range is within the typical fluctuations of the stock price.
Stakeholder Impact
- The sale of shares by the CFO may have a minor impact on the stock price, but it is not expected to be significant.
- The transaction is part of a standard compensation practice and should not negatively affect employee morale.
Key Dates
| Date | Description |
|---|---|
| 01/17/2025 | Date of the stock sale transaction. |
| 01/21/2025 | Date of the stock sale transaction. |
| 01/22/2025 | Date the Form 4 was signed. |
Keywords
Pliant Therapeutics, insider trading, Form 4, stock sale, Keith Lamont Cummings, executive compensation, Rule 10b5-1, tax obligations, restricted stock units, employee stock purchase plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.